Verapamil effect on phenytoin pharmacokinetics in rats

Epilepsy Research

Volumn 107, Issue 1-2, 2013, Pages 51-55

  Alvariza, Silvana ^a   Fagiolino, Pietro ^a   Vázquez, Marta ^a   Rosillo de la Torre, Argelia ^b   Orozco Suárez, Sandra ^c   Rocha, Luisa ^b  

^a UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

^c 21st Century National Medical Center of the Mexican Institute of Social Security   (Mexico)

Author keywords

Interaction on efflux transporter; Multiple intraperitoneal dose administration; Phenytoin; Verapamil

Indexed keywords

HYDANTOIN; PHENYTOIN; VERAPAMIL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG POTENTIATION; FEMALE; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

INTERACTION ON EFFLUX TRANSPORTER; MULTIPLE INTRAPERITONEAL DOSE ADMINISTRATION; PHENYTOIN; VERAPAMIL;

ANIMALS; ANTICONVULSANTS; BLOOD-BRAIN BARRIER; DRUG INTERACTIONS; FEMALE; PHENYTOIN; RATS; RATS, SPRAGUE-DAWLEY; VERAPAMIL;

EID: 84886946123     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2013.09.001     Document Type: Article

References (18)

1. Alvariza, S., Orozco Suárez, S., Feria Romero, I., Vázquez, M., Fagiolino, P., 2013. Efflux transporter overexpression after chronic administration of phenytoin in rats (submitted for publication).
2. Brouwers P.J., de Boer L.E., Guchelaar H.J. Ciprofloxacin-phenytoin interaction. Annals of Pharmacotherapy 1997, 31:498.
3. Chaudhry A.S., Urban T.J., Lamba J.K., Birnbaum A.K., Remmel R.P., Subramanian M., Strom S., You J.H., Kasperaviciute D., Catarino C.B., Radtke R.A., Sisodiya S.M., Goldstein D.B., Shuetz E.G. CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose. Journal of Pharmacology and Experimental Therapeutics 2010, 332:599-611.
4. Chetty M., Miller R., Seymour M.A. Phenytoin auto-induction. Therapeutic Drug Monitoring 1998, 20:60-62.
5. Fagiolino P., Vázquez M., Eiraldi R., Maldonado C., Scaramelli A. Efflux transporter influence on drug metabolism: theoretical approach for bioavailability and clearance prediction. Clinical Pharmacokinetics 2011, 50:75-80.
6. Lazarowski A., Czornyj L., Lubieniecki F., Girardi E., Vázquez S., D'Giano C. ABC-transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsy 2007, 48:140-149.
7. Lindell M., Lang M., Lennernäs H. Expression of genes encoding for drug metabolising cytochrome P450 enzymes and P-glycoprotein in the rat small intestine: comparison to the liver. European Journal of Drug Metabolism and Pharmacokinetics 2003, 28:41-48.
8. Lolin Y.I., Ratnaraj N., Hjelm M., Patsalos P.N. Antiepileptic drug pharmacokinetics ad neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: phenytoin. Epilepsy Research 1994, 19:99-110.
9. Lu Y., Yan Y., Wang X.F. Antiepileptic drug-induced multidrug resistance P-glycoprotein overexpression in astrocytes cultured from rat brains. Chinese Medical Journal 2004, 117:1682-1686.
10. Maldonado C., Fagiolino P., Vázquez M., Eiraldi R., Alvariza S., Bentancur C., Álvarez P. Time-dependent and concentration-dependent upregulation of carbamazepine efflux transporter. A preliminary assessment from salivary drug monitoring. Latin American Journal of Pharmacy 2011, 30:908-912.
11. McLeod R., Trinkle R. Comment: unexpectedly low phenytoin concentration in a patient receiving ciprofloxacin. Annals of Pharmacotherapy 1998, 32:1110-1111.
12. Miller R., Bill P.L., Du Toit J. Phenytoin auto-induction? Case reports. South African Medical Journal 1989, 75:332-333.
13. Miller D.S., Bauer B., Hartz A.M.S. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve CNS pharmacotherapy. Pharmacological Reviews 2008, 60:196-209.
14. Neerati P., Ganji D., Bedada S.K. Study on in situ and in vivo absorption kinetics of phenytoin by modulating P-glycoprotein with verapamil in rats. European Journal of Pharmaceutical Sciences 2011, 44:27-31.
15. Potschka H., Löscher W. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia 2001, 42:1231-1240.
16. Savio E., Fagiolino P., Solana G., Parente E., León A. Development of wáter/oil emulsion. Bioavailability in rats. STP Pharma Sciences 1991, 1:379-385.
17. Van Vliet E.A., van Schaik R., Edelbroek P.M., Redeker S., Aronica E., Wadman W.J., Marchi N., Vezzani A., Gorter J.A. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 2006, 47:672-680.
18. Wen T., Liu Y.-C., Yang H.-W., Liu H.-Y., Liu X.-D., Wang G.-J., Xie L. Effect of 21-day exposure of phenobarbital, carbamazepine and phenytoin on P-glycoprotein expression and activity in the rat brain. Journal of the Neurological Sciences 2008, 270:99-106.